Clinical Trial Update: An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease [Phase 2]

View source ↗

Summary

Phase 2 open-label safety and tolerability study of AIN457 in moderate to severe Crohn's disease was terminated; results were posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• AIN457

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Crohn's Disease, Inflammatory Bowel Disease | Phase 2 | Status: TERMINATED | Results posted: 2021-07-12